Drug Profile
Research programme: synthetic tolerogenic vaccines - Cartesian Therapeutics
Alternative Names: SEL-701; t2SVP vaccinesLatest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Cancer vaccines; Parasitic vaccines; Synthetic vaccines
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Type 1 diabetes mellitus
- Discontinued Cervical cancer; Chlamydial infections; Head and neck cancer; Malaria
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Cervical cancer in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Chlamydial infections (Prevention) in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Head and neck cancer in USA (Parenteral)